🚨 ESMO 2026 | 值得关注的妇科肿瘤学 TOP 10 试验！
从无化疗免疫治疗到新一代ADC，#ESMO26可能重塑妇科肿瘤学！
🔥 我的十大重点试验，按癌症亚型分类：
🔴 子宫内膜癌
TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs 医生选择方案，用于复发/晚期疾病。
KEYNOTE-C93 (LBA12) | Pembrolizumab单药 vs 化疗，用于1L dMMR疾病。能否免用化疗？
NRG-GY020 (1239O) | 辅助放疗 ± pembrolizumab，用于早期dMMR疾病。
Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + 免疫治疗，用于铂类治疗后pMMR疾病。
🔵 卵巢癌
BEHOLD-1 (LBA41) | Mocertatug rezetecan，一款B7-H4 ADC，用于铂类耐药疾病。
REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab，用于铂类耐药疾病。
REJOICE-Ovarian01 (1331P) | Raludotatug deruxtecan更新后的疗效和安全性。
BEHOLD-1生物标志物分析 (1248RO) | 哪些生物标志物可预测对B7-H4 ADC治疗的应答？
🟣 宫颈癌
CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs 化疗，用于复发/转移性疾病。
EMPOWER-Cervical 1 (1250O) | 基于cemiplimab的策略及长期结局。
⭐ 我的三大重点关注试验：
KEYNOTE-C93 | TroFuse-005 | BEHOLD-1
哪项试验最有可能改变你的临床实践？
@ESMO_open @myesmo @ASCO @oncoalert
#ESMO26 #GynOnc #Oncology
2438 浏览 · 30 赞 · 9 转发 · 1 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgRaludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Updated results from the phase 2 dose-optimization part of REJOICE-Ovarian01
https://esmocongress.esmo.orgCLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.org🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open在 X 查看被引用的帖子
- E Lambrechts@EgidiusLambrech
@DrRishabhOnco you have a mistake on LBA45
来源：Dr Rishabh Jain · x.com